Biosafety Level 4 (BSL-4)

Biosafety Level 4 (BSL-4) is the highest and most restrictive of the four graded laboratory-containment tiers defined by the CDC/NIH publication Biosafety in Microbiological and Biomedical Laboratories (BMBL, 6th edition, 2020). A protocol is assigned BSL-4 when it involves agent(s) that pose a high risk of life-threatening disease, for which no vaccine or treatment is routinely available, and for which aerosol transmission — or an unpredictable transmission risk related to a known aerosol-transmissible agent — is a realistic exposure route. This page covers what BSL-4 specifically requires; for how BSL-4 relates to BSL-1 through BSL-3 and how a Biosafety Level is formally assigned, see the general Biosafety Level (BSL) entry, and for the moderate-hazard, non-aerosol tier at the opposite end of the everyday-lab spectrum, see Biosafety Level 2 (BSL-2) — neither is repeated here.

What makes a protocol BSL-4

BSL-4 is reserved for a small number of agents worldwide and is not defined by exotic origin alone, but by the combination of consequence and controllability: the disease the agent causes is frequently fatal, no licensed vaccine or effective treatment exists (or existing countermeasures are not reliably available), and the agent transmits efficiently by the inhalation of infectious aerosols, or its transmission risk cannot be predicted with confidence. Where BSL-3 accepts that engineered airflow and biosafety-cabinet use can adequately contain an inhalation-risk agent that is nonetheless treatable, BSL-4 assumes that a containment failure could be both undetectable until too late and unmanageable afterward — so it removes the possibility of direct personnel exposure to the open agent entirely, either by placing a physical barrier (a Class III cabinet) between the worker and the agent at all times, or by placing the worker inside a sealed, independently ventilated positive-pressure suit.

Typical agents handled at BSL-4

Agents assigned BSL-4 containment are viral hemorrhagic fever agents and a small number of other agents that meet the severity/no-countermeasure/aerosol-risk criteria above, including Ebola virus and other filoviruses, Marburg virus, Lassa virus, Crimean-Congo hemorrhagic fever virus, and Nipah virus. Variola virus (smallpox) is also a BSL-4 agent, though live virus is retained at only two WHO-authorized repositories worldwide (the CDC in the United States and a Russian state research center), not distributed to research laboratories generally. This is a representative, not exhaustive, list; nearly all BSL-4 agents are also regulated as HHS or USDA/APHIS select agents or toxins under the Federal Select Agent Program, and the actual containment determination for any specific agent or protocol is made by an Institutional Biosafety Committee (IBC) risk assessment, not inferred from a list alone. The United States operates on the order of a dozen active BSL-4 facilities, most affiliated with federal agencies (e.g., CDC, USAMRIID) or a small number of university-based national/regional biocontainment laboratories — BSL-4 capacity is deliberately scarce and heavily regulated, unlike BSL-1/BSL-2 space, which exists in most research institutions.

Required practices at BSL-4

BSL-4 builds cumulatively on BSL-1 through BSL-3 practice rather than replacing it, adding controls aimed at eliminating any pathway for an undetected exposure or release:

• Two-person (buddy) rule. No one works alone in a BSL-4 laboratory or suit area; personnel are present and visible to each other, or under continuous video/communication monitoring, throughout agent work.
• Restricted, logged access. Entry is limited to specifically authorized, medically cleared personnel, with entry and exit logged for every occasion the containment area is entered.
• Change-in / shower-out. Personnel change out of street clothing into dedicated laboratory clothing before entry, and must pass through a personnel decontamination shower before leaving the containment area — a chemical shower for a suit-lab worker exiting a positive-pressure suit, or a standard shower for a cabinet-line worker.
• Occupational health and medical surveillance. Personnel are enrolled in an agent-specific occupational health program, which typically includes baseline serum banking, symptom-reporting protocols, and a defined medical response plan for a suspected exposure.
• A facility- and agent-specific biosafety manual covering emergency procedures (power loss, suit failure, spill, injury) that personnel must be trained on and drilled against before working independently.
• Decontamination of all materials — equipment, waste, and effluent — before they leave the containment barrier, with no exception for items that appear uncontaminated.

Safety equipment: suit lab vs. Class III cabinet line

The BMBL recognizes two equivalent primary-containment approaches for BSL-4 work, and a facility is generally built around one or the other rather than mixing both for the same procedure:

• Cabinet-line laboratory. All agent manipulation is performed inside a gas-tight Class III biosafety cabinet, physically sealed to the room and connected to the facility’s dedicated, HEPA-filtered exhaust. The agent is never directly exposed to the room air or to the worker; the worker’s hands enter the cabinet through attached glove ports. Standard BSL-3 PPE and practices apply outside the cabinet.
• Suit laboratory. Personnel work at the open bench, inside the containment room itself, wearing a full-body, positive-pressure, HEPA-filtered supplied-air suit. The suit’s positive pressure relative to the room ensures that if the suit is breached, air flows outward through the breach rather than contaminated room air flowing in. Suit-lab personnel pass through an airlock and a chemical decontamination shower (while still suited) before removing the suit and showering again on the way out.

Facility features required at BSL-4

A BSL-4 laboratory is a dedicated, physically isolated facility or a separate, sealable building, or a clearly demarcated and structurally isolated zone within a larger building — not a room retrofitted within general laboratory space. Beyond BSL-3’s engineering controls, BSL-4 facilities are expected to have: a dedicated, redundant supply and exhaust air-handling system serving only the BSL-4 zone, with HEPA filtration on exhaust air (and typically on supply air as well) and backup power/fan redundancy so a single equipment failure cannot cause loss of directional airflow; a double-door, pass-through autoclave or equivalent validated decontamination system for anything leaving the space that cannot pass through the personnel shower; an effluent decontamination system that treats liquid waste (including, in a suit lab, shower and sink discharge) before it enters the sanitary sewer; sealed penetrations and a maintained negative pressure differential relative to all adjacent, non-BSL-4 space; and continuous, alarmed monitoring of airflow direction, pressure differentials, and life-support systems (in a suit lab) with a documented emergency response plan for any alarm condition.

Who assigns and oversees BSL-4

As with every BSL, the containment level is formally assigned through an institution’s Institutional Biosafety Committee (IBC) risk assessment under the NIH Guidelines, before laboratory work may begin — the IBC’s composition, registration process, and general relationship to BSL assignment are covered in full on the general Biosafety Level (BSL) page rather than repeated here. For BSL-4 specifically, IBC oversight is layered underneath, not instead of, additional federal oversight that applies to nearly every BSL-4 agent: registration and inspection under the Federal Select Agent Program (jointly administered by CDC and USDA APHIS) for possession, use, and transfer of a select agent or toxin, and, for most BSL-4 agents, classification as Dual Use Research of Concern (DURC) Category 1 — a designation that by policy captures all regulated select agents and any human pathogen recommended for BSL-3 or BSL-4 handling under the current BMBL. A single BSL-4 protocol therefore typically requires active registration and periodic re-review from the IBC, the institution’s Biosafety Officer, and the Federal Select Agent Program simultaneously, in addition to whatever institutional DURC review policy applies — this is a materially heavier compliance load than BSL-1 through BSL-3 work generally carries, and a research administrator supporting BSL-4 work should expect to track all of these tracks in parallel rather than treat IBC approval alone as sufficient to begin.

Worked examples

Example 1. A national biocontainment research laboratory studying Ebola virus pathogenesis in an animal model performs all agent manipulation either inside a Class III biosafety-cabinet line or by personnel working in positive-pressure supplied-air suits. The facility’s dedicated, redundant HEPA-filtered exhaust system and effluent-decontamination system operate independently of the rest of the building, entry is logged and limited to medically cleared, suit-trained personnel working in pairs, and every suit-lab worker passes through the facility’s chemical decontamination shower before removing the suit and exiting.

Example 2. A laboratory performing diagnostic confirmation testing on a specimen from a suspected Marburg virus case handles that specimen at BSL-4 until the diagnosis is ruled out or the sample is inactivated, because the specimen’s infectious status and the absence of a licensed vaccine or treatment place it within BSL-4’s risk criteria by default. The work also triggers Federal Select Agent Program obligations in addition to the IBC’s own registration and risk-assessment process, given Marburg virus’s status as an HHS select agent.

Counter-example

Work with SARS-CoV-2 is generally not a BSL-4 example, even though the virus is efficiently aerosol-transmissible and can cause severe, sometimes fatal respiratory disease: because effective vaccines and treatments are now available and the agent does not otherwise meet BSL-4’s no-available-countermeasure criterion, CDC/NIH guidance places routine diagnostic work at BSL-2 and virus isolation, propagation, and much research work at BSL-3 with enhanced respiratory-protection practices, not BSL-4. As with the BSL-2/BSL-3 boundary, agent identity and disease severity alone don’t determine the level — the combination of severity, countermeasure availability, and transmission route does, evaluated through an institution-specific IBC risk assessment.

Related terms

• Biosafety Level (BSL) — the full four-tier system (BSL-1 through BSL-4) and how a level is assigned
• Biosafety Level 2 (BSL-2) — the moderate-hazard, non-aerosol containment tier most everyday microbiology and clinical laboratory work falls under
• IRB (Institutional Review Board)
• Scientific Review Committee
• Laboratory Safety (OSHA Chemical Hygiene Plan) — the parallel OSHA framework for chemical, rather than biological, laboratory hazards

For the broader compliance context this term sits within, see the Integrity & Compliance cluster page.